NCT03159416 - A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 22, 2017

Primary Completion Date

March 24, 2018

Study Completion Date

March 24, 2018

Conditions

Renal Impairment

Interventions

DRUG

Inclisiran

Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.

Trial Locations (2)

Unknown

Auckland Clinical Studies Limited, Auckland

Christchurch Clinical Studies Trust, Christchurch